Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

YKL-40 in patients with end-stage renal disease receiving haemodialysis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Biomarkers in patients with Takotsubo cardiomyopathy compared to patients with acute anterior ST-elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical usefulness of FDG-PET/CT for identification of abnormal extra-cardiac foci in patients with infective endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Incidence of Ischemic Stroke in Individuals With and Without Aortic Valve Stenosis: A Danish Retrospective Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40.

METHODS: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment.

RESULTS: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL-1(IQR: 193-291 µgL-1) before HD treatment and 198 µgL-1(IQR: 147-258 µgL-1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2-7.3, p < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1-4.5, p = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment.

CONCLUSION: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.

Original languageEnglish
JournalBiomarkers
Volume23
Issue number4
Pages (from-to)357-363
Number of pages7
ISSN1354-750X
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 53412829